Advanced Search
Published: Jul 20, 2018 DOI: 10.21769/BioProtoc.2936 Views: 6214
Edited by: Longping Victor Tse Reviewed by: Masfique Mehedi
Abstract
This protocol describes the rapid and safe production of lentiviral pseudotypes characterized by a lentiviral core containing a reporter, in conjunction with avian influenza haemagglutinin (HA) and human neuraminidase (NA) glycoproteins on the surface. Production is optimized with Endofectin LentiTM transfection reagent in 6-well plate format. These pseudotyped viruses can be employed for serological assays of surface glycoproteins HA and NA. They can be efficiently used to perform the ELLA (Enzyme-linked lectin assay) to measure NA inhibiting antibodies in lieu of using reassortant virus or Triton X-100 inactivated wild-type virus as source of antigen, which may require higher biosafety levels.
Keywords: ELLABackground
The production of influenza virus pseudotypes has been extensively described previously (Nefkens et al., 2007; Temperton et al., 2007; Carnell et al., 2015). The need for a safe and rapid system to evaluate antibodies targeting the NA via the ELLA assay, avoiding the employment of reassortant mismatched virus or wild-type virus, has been met by producing influenza NA bearing pseudotypes (Prevato et al., 2015). A recent study (Biuso et al., 2017) confirmed that the co-expression of HA with NA improves the release of newly formed pseudotyped lentiviruses. Here we report a simple, widely applicable and optimized protocol for PV production by using the Endofectin LentiTM transfection reagent in 6-well plate format, and the methodology to perform an ELLA assay with the resulting influenza pseudotypes. While PV production for HA-based assays has made use of the lentiviral genome containing a reporter gene, the ELLA assay utilizes solely the surface NA glycoprotein, rendering a PV-incorporated reporter irrelevant to this protocol. The original ELLA assay from 1990 was recently improved (Couzens et al., 2014). This assay enables the detection of exposed galactose residues resulting from the enzymatic action of NA on sialic acids present on the fetuin substrate. This assay allows the measurement of NA inhibiting antibodies, through detection of a drop in enzymatic NA activity. The ELLA overcomes the limits of the cumbersome thiobarbituric acid assay (TBA) that employs hazardous materials, allowing for large-scale screening of serum samples. The basis of the assay is simple, 96-well plates are coated in the carbohydrate fetuin, which is then exposed to NA through NA bearing PV. The NA enzyme cleaves terminal sialic acid residues from the fetuin, exposing galactose that is then bound by the peanut agglutinin from Arachis hypogeal, conjugated to horseradish peroxidase (PNA-HRPO). This reagent then forms the basis for colorimetric reading of NA activity by a spectrophotometer. This activity can then be knocked down using an inhibitor (such as antibodies found in human sera) in subsequent assays. The described protocol combines the ability to screen a large number of sera through the ELLA assay, with a simple and safe lentiviral pseudotype production protocol. NA targeting antibodies are typically neglected in current influenza vaccines (compared to HA targeting antibodies), despite being shown to limit influenza symptoms and transmission (Marcelin et al., 2011 and 2012; Wohlbold and Krammer, 2014).
Materials and Reagents
Equipment
Procedure
Category
Immunology > Antibody analysis > Antibody function
Immunology > Antibody analysis > Antibody-antigen interaction
Biochemistry > Protein > Immunodetection
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Share
Bluesky
X
Copy link